Breakthroughs in Pediatric Cholestasis Management
When you look at the sheer numbers, the US Alagille Syndrome Market is witnessing a paradigm shift in how we treat chronic pruritus (itching) associated with this rare condition. For decades, treatment was limited to symptom management, but in 2026, the introduction of "IBAT Inhibitors" has transformed the standard of care. These drugs prevent the reabsorption of bile acids, significantly...
0 Kommentare 0 Geteilt 22 Ansichten 0 Bewertungen